62402-24-8

Basic information

• Product Name: N-(2-PYRIDYLMETHYL)GLYCINE ETHYL ESTER
• Synonyms: ETHYL N-(2-PYRIDYLMETHYL)GLYCINATE;N-(2-PYRIDYLMETHYL)GLYCINE ETHYL ESTER;N-(2-PICOLYL)GLYCINE ETHYL ESTER;Pyridylmethylglycineethylester;Ethyl N-(2-Pyridylmethyl)glycinate N-(2-Picolyl)glycine Ethyl Ester;N-(2-Pyridylmethyl)glycine Ethyl Ester
• CAS NO: 62402-24-8
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.23
• Mol File: 62402-24-8.mol

Chemical Properties

• Boiling Point: 134 °C(Press: 0.2 Torr)
• Appearance: /
• Density: 1.10
• Refractive Index: 1.5050-1.5070
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.40±0.20(Predicted)
• CAS DataBase Reference: N-(2-PYRIDYLMETHYL)GLYCINE ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-PYRIDYLMETHYL)GLYCINE ETHYL ESTER(62402-24-8)
• EPA Substance Registry System: N-(2-PYRIDYLMETHYL)GLYCINE ETHYL ESTER(62402-24-8)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 62402-24-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
N-(2-Pyridylmethyl)glycine ethyl ester is used as a key building block for the synthesis of pharmaceutical drugs. Its unique chemical structure allows it to be incorporated into the development of new medications, potentially enhancing their efficacy and safety.
Used in Chemical Research:
In the field of chemical research, N-(2-Pyridylmethyl)glycine ethyl ester is utilized for its distinctive properties, contributing to the advancement of scientific understanding and the discovery of novel chemical compounds and reactions.
Used in Organic Synthesis:
N-(2-PYRIDYLMETHYL)GLYCINE ETHYL ESTER is also employed in organic synthesis, where its solubility and reactivity make it a valuable component in the creation of complex organic molecules for various applications.
Safety Considerations:
As with many chemical compounds, N-(2-Pyridylmethyl)glycine ethyl ester should be handled with care due to its potential harmful effects if swallowed, inhaled, or comes in contact with skin or eyes. Proper safety measures and precautions are essential during its use in laboratories and industrial settings.

Upstream product

• 3731-51-9 2-(Aminomethyl)pyridine 
• 105-36-2 ethyl bromoacetate 
• 84359-11-5 2-(aminomethyl)pyridine hydrochloride 
• 105-39-5 chloroacetic acid ethyl ester 
• 100-70-9 2-Cyanopyridine 

Downstream Products

• 109814-50-8 octahydro-pyrido[1,2-a]pyrazin-4-one 
• 1018330-10-3 2-(N-isopropyl-N-((2-pyridyl)methyl)aminomethyl)-6-(N-(ethoxycarbonylmethyl)-N-((2-pyridyl)methyl)aminomethyl)-4-methylphenol 
• 1416966-82-9 N-[4-(Benzothiazol-2-yl)phenylaminocarbonylbutyl]-N-(pyridin-2-ylmethyl)aminoacetic acid 
• 1016644-88-4 ethyl [[(4-methyl-2-phenyl-1,3-oxazol-5-yl)carbonyl](pyridin-2-ylmethyl)amino]acetate 

Relevant articles and documents

An inorganic helix [Mn(IPG)(MeOH)](n)[PF6](n): Structural and magnetic properties of a syn-anti carboxylate-bridged manganese(II) chain involving a tetradentate ligand

The crystal structure of an infinite inorganic chain consisting of Mn(II) and an N-centered tripodal ligand N,N-(2-pyridylmethyl)[(1- methylimidazol-2-yl)-methyl]glycinate is presented. It exhibits a chiral helical structure with a pitch of two monomeric units (each monomeric unit containing one Mn atom). Each manganese is connected to its neighbor through a carboxylate bridge in a syn-antigeometry. Around each manganese center, two carboxylates bind in a cis geometry. This peculiar bridging geometry (syn- anti cis) provides a broken-line chain, running in a zig-zag manner along the b axis of the P21 space group. The magnetic properties have been investigated. They show a pseudo-2D magnetic structure, with one major pathway along the chain and an inter-chain minor one. The intrachain coupling is a weak antiferromagnetic interaction (J/k = -0.25). This low value is entirely consistent with the geometry of the bridge. The interchain coupling is a weaker antiferromagnetic coupling (J'/k = -0.11) and could be mediated through π-π interactions between pyridine and imidazole from two adjacent helixes.

The influence of ZnII coordination sphere and chemical structure over the reactivity of metallo-β-lactamase model compounds

A systematic study of the influence of the first coordination sphere over the reactivity and structure of metallo-β-lactamase (MβL) monozinc model complexes is reported. Three ZnII complexes with tripodal ligands forming the series [Zn(N-NNN)], [Zn(N-NNS)], and [Zn(N-NNO)] where N-NNX represents the tripodal donor atoms were investigated regarding their ability to mimic MβL. The tripodal series was inspired by MβL active sites in the respective subclasses, representing the (His, His, His) Zn1 site present in B1 and B3 subclasses, (His, His, Asp) present in the B3 subclass site and the thiolate present in B1 and B2 sites. The results were supported by electronic structure calculations. XAS analysis demonstrated that the ZnII electronic deficiency significantly changes in the order [Zn(N-NNS)] II electronic details must be considered in the design of new MβL models that will further aid in the design of clinically useful inhibitors.

Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure-Activity Relationships and Optimization

Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: The calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure-activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists.

Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1

Eukaryotic mRNA contains a 3′ poly(A) tail, which plays important roles in the regulation of mRNA stability and translation. Well-characterized enzymes involved in the shortening of the poly(A) tail include the multi-subunit Ccr4-Not deadenylase, which contains the Caf1 (Pop2) and Ccr4 catalytic components, and poly(A)-specific ribonuclease (PARN). Two Mg2+ ions present in the active sites of these ribonucleases are required for RNA cleavage. Here, we report the discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as (sub)micromolar inhibitors of Caf1.

Unsymmetrical dizinc complexes as models for the active sites of phosphohydrolases

The unsymmetrical dinucleating ligand 2-(N-isopropyl-N-((2-pyridyl)methyl) aminomethyl)-6-(N-(carboxylmethyl)-N-((2-pyridyl)methyl)aminomethyl) -4-methylphenol (IPCPMP or L) has been synthesized to model the active site environment of dinuclear metallohydrolases. It has been isolated as the hexafluorophosphate salt H4IPCPMP(PF6)2· 2H2O (H4L), which has been structurally characterized, and has been used to form two different Zn(ii) complexes, [{Zn2(IPCPMP) (OAc)}2][PF6]2 (2) and [{Zn2(IPCPMP) (Piv)}2][PF6]2 (3) (OAc = acetate; Piv = pivalate). The crystal structures of 2 and 3 show that they consist of tetranuclear complexes with very similar structures. Infrared spectroscopy and mass spectrometry indicate that the tetranuclear complexes dissociate into dinuclear complexes in solution. Potentiometric studies of the Zn(ii):IPCPMP system in aqueous solution reveal that a mononuclear complex is surprisingly stable at low pH, even at a 2:1 Zn(ii):L ratio, but a dinuclear complex dominates at high pH and transforms into a dihydroxido complex by a cooperative deprotonation of two, probably terminally coordinated, water molecules. A kinetic investigation indicates that one of these hydroxides is the active nucleophile in the hydrolysis of bis(2,4-dinitrophenyl)phosphate (BDNPP) enhanced by complex 2, and mechanistic proposals are presented for this reaction as well as the previously reported transesterification of 2-hydroxypropyl p-nitrophenyl phosphate (HPNP) promoted by Zn(ii) complexes of IPCPMP.

Towards Gram-negative antivirulence drugs: New inhibitors of HldE kinase

Gram-negative bacteria lacking heptoses in their lipopolysaccharide (LPS) display attenuated virulence and increased sensitivity to human serum and to some antibiotics. Thus inhibition of bacterial heptose synthesis represents an attractive target for the development of new antibacterial agents. HldE is a bifunctional enzyme involved in the synthesis of bacterial heptoses. Development of a biochemical assay suitable for high-throughput screening allowed the discovery of inhibitors 1 and 2 of HldE kinase. Study of the structure-activity relationship of this series of inhibitors led to highly potent compounds.

Symmetrical and unsymmetrical dizinc complexes as models for the active sites of hydrolytic enzymes

Dinuclear carboxylate-bridged zinc complexes of one symmetric and one asymmetric phenolate-based ligand catalyse the transesterification of 2-hydroxypropyl-p-nitrophenyl phosphate (HPNP) at different rates, with an unsymmetrical complex being more active than a symmetric one. The Royal Society of Chemistry.

Synthesis, characterization, and biological evaluation of M(I)(CO) 3(NNO) complexes (M = Re, 99mTc) conjugated to 2-(4-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals

The synthesis and biological evaluation of new M(I)(CO)3(NNO) (M = Re, 99mTc) complexes attached to the antitumor agent 2-(4-aminophenyl)benzothiazole are reported. The fluorescent rhenium complex enters MCF-7 breast cancer cells but

Peptide compound and its preparation

Novel peptides of the formula (I") STR1 in which R1 is hydrogen or acyl, R2c is lower alkyl, R3c is optionally N-substituted indolylmethyl, R4 is hydrogen, lower alkyl, C6-10 ar(lower)alkyl, amino(lower)alkyl, protected amino (lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl or optionally substituted heterocyclic (lower)alkyl, R5 is carboxy, protected carboxy, carboxy(lower)alkyl or protected carboxy(lower)alkyl, R7 is hydrogen or lower alkyl, and A is --O--, --NH--, lower alkylamino or lower alkylene, or a pharmaceutically acceptable salt thereof are disclosed. Additionally, the preparation of such peptides is described. The peptides are used to treat endothelin mediated diseases such as hypertension.